CRISPR Therapeutics shares are trading lower after TD Cowen downgraded the stock from Market Perform to Underperform and announced a $30 price target.
Portfolio Pulse from Benzinga Newsdesk
CRISPR Therapeutics' stock (CRSP) trades lower following a downgrade by TD Cowen from Market Perform to Underperform, with a new price target set at $30.

December 11, 2023 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CRISPR Therapeutics' stock price is likely to experience downward pressure in the short term due to the downgrade by TD Cowen from Market Perform to Underperform and a lower price target of $30.
Analyst downgrades typically lead to a negative perception among investors, potentially causing a decrease in stock price. The setting of a lower price target further reinforces the expectation of a decline.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100